drugset / Trial / NCT04337593
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.
Timeline
- Start
- 2020-06-01
- Primary completion
- 2022-05-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basiliximab | Monoclonal antibody | 20 mg | — |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 unknown | — |